Sort   by:  
 Page size 
ProteomicsConfirmation of ZAK as covalent target of Ibrutinib
The goal of this experiment was the confirmation of ZAK as a covalent target of Ibrutinib by an affinity enrichment experiment with a linkable analogue of Ibrutinib.
ORGANISM(S): Homo sapiens (Human) 
2017-10-13 | PXD007638 | Pride
Lysate-based assay Linkable ibrutinib affinity enrichment Sds elution vs bead trypsinationlc-ms/ms Ibrutinib Ramos b-lymphocyte lysate 
ProteomicsABPP of Ibrutinib Resistance in B Cell Malignancies
Ibrutinib,a novel Bruton'styrosine kinase inhibitor, demonstrated high response rates in B-cell lymphomas but a growing number of ibrutinib treated patients relapse with resistance, fulminant progression and accelerated mortality. Using chemical proteomics and a high-throughput ex vivo assay in a re...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005734 | Pride
Ibrutinib Activity-based protein profiling B-cell cancers Lc-ms/ms 
TranscriptomicsTargeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improve...
ORGANISM(S): Homo sapiens 
2026-03-10 | E-MTAB-16241 | biostudies-arrayexpress
ProteomicsIdentification of the covalent binding site of Ibrutinib and 5Z-7-Oxozeaenol to ZAK
The goal of this experiment was to identify the reaction site of Ibrutinib and 5Z-7-Oxozeaenol to ZAK by determination of mass shifts according to a covalent modification by the inhibitors using mass spectrometry.
ORGANISM(S): Homo sapiens (Human) 
2017-10-13 | PXD007752 | Pride
Ibrutinib 5z-7-oxozeaenol Cys150 Recombinant zak Cys22 Covalent modification 
GenomicsEGR1-mediated ibrutinib resistance
EGR1-mediated ibrutinib resistance
PRJNA925145 | ENA
ProteomicsProteoform-level drug target landscapes demonstrates a wider spectrum of ibrutinib targets
In this study, we investigated the target landscape of the drug ibrutinib using thermal proteome profiling (TPP) and proteoform detection. Our findings demonstrated that ibrutinib interacts with multiple proteoforms, beyond its known targets. Specifically, we identified interactions related to immun...
ORGANISM(S): Homo sapiens (Human) 
2024-11-24 | PXD047187 | Pride
Acute lymphoblastic leukemia Ibrutinib Proteoforms Thermal proteoform profiling 
TranscriptomicsChromatin structure analysis for two patients on Ibrutinib and showing disease progression in chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in developed countries. Ibrutinib (PCI-32765), a specific and irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) represents a major step forward in the treatment of CLL, but cases of resistance are emerging. We ha...
ORGANISM(S): Homo sapiens 
2020-09-01 | E-MTAB-8220 | biostudies-arrayexpress
GenomicsIbrutinib in CLL
Clonal evolution in CLL patients treated with ibrutinib
PRJEB32120 | ENA
GenomicsIbrutinib induces a global chromatin reorganisation in chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in developed countries. Ibrutinib (PCI-32765), a specific and irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) represents a major step forward in the treatment of CLL. We have undertaken a detailed analysis of t...
ORGANISM(S): Homo sapiens 
2019-06-01 | E-MTAB-6410 | biostudies-arrayexpress
ProteomicsThe conformational state of PLCγ cSH2-linker contributes to Ibrutinib resistance
Mutations in PLCγ, a substrate of the tyrosine kinase BTK, are often found in patients who develop resistance to the BTK inhibitor Ibrutinib. However, the mechanisms by which these PLCγ mutations cause Ibrutinib resistance are unclear. Under normal signaling conditions, BTK mediated phosphorylation ...
ORGANISM(S): Rattus norvegicus (Rat) 
2022-01-19 | PXD028923 | Pride
Plcγ  phospholipase c gamma  ibrutinib resistance  allostery  hdx-ms  hydrogen/deuterium exchange mass spectrometry  nmr  sh2 domain. 
Sort   by:  
 Page size